Mawer Investment Management Ltd. Has $54.28 Million Stake in Gilead Sciences (GILD)

Mawer Investment Management Ltd. lifted its holdings in shares of Gilead Sciences (NASDAQ:GILD) by 5.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 719,997 shares of the biopharmaceutical company’s stock after buying an additional 39,517 shares during the quarter. Mawer Investment Management Ltd. owned about 0.06% of Gilead Sciences worth $54,281,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. Heritage Wealth Advisors grew its holdings in Gilead Sciences by 2.5% during the fourth quarter. Heritage Wealth Advisors now owns 26,523 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 642 shares during the period. Hanson & Doremus Investment Management grew its holdings in Gilead Sciences by 35.7% during the fourth quarter. Hanson & Doremus Investment Management now owns 2,461 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 648 shares during the period. Griffin Asset Management Inc. grew its holdings in Gilead Sciences by 2.5% during the fourth quarter. Griffin Asset Management Inc. now owns 27,160 shares of the biopharmaceutical company’s stock valued at $1,946,000 after purchasing an additional 650 shares during the period. First Capital Advisors Group LLC. grew its holdings in Gilead Sciences by 9.1% during the fourth quarter. First Capital Advisors Group LLC. now owns 7,857 shares of the biopharmaceutical company’s stock valued at $563,000 after purchasing an additional 653 shares during the period. Finally, Wedbush Securities Inc. grew its holdings in Gilead Sciences by 1.0% during the fourth quarter. Wedbush Securities Inc. now owns 65,102 shares of the biopharmaceutical company’s stock valued at $4,664,000 after purchasing an additional 660 shares during the period. Institutional investors own 78.16% of the company’s stock.

Shares of GILD stock opened at $67.60 on Friday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.75 and a current ratio of 2.84. The firm has a market capitalization of $87.83 billion, a PE ratio of 7.90, a price-to-earnings-growth ratio of -5.87 and a beta of 1.19. Gilead Sciences has a 12 month low of $67.01 and a 12 month high of $67.62.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $1.48 EPS for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.19). The business had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.40 billion. Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The business’s revenue for the quarter was down 21.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.23 EPS. analysts anticipate that Gilead Sciences will post 5.75 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 28th. Stockholders of record on Friday, June 15th will be given a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.37%. The ex-dividend date is Thursday, June 14th. Gilead Sciences’s dividend payout ratio is presently 26.64%.

In other news, CFO Robin L. Washington sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total value of $401,550.00. Following the sale, the chief financial officer now owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director John Francis Cogan sold 5,836 shares of the business’s stock in a transaction on Friday, May 4th. The stock was sold at an average price of $65.09, for a total transaction of $379,865.24. Following the completion of the sale, the director now directly owns 58,455 shares in the company, valued at approximately $3,804,835.95. The disclosure for this sale can be found here. In the last three months, insiders sold 241,102 shares of company stock worth $18,237,884. 1.30% of the stock is currently owned by insiders.

A number of research analysts recently issued reports on the stock. Barclays decreased their price objective on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 2nd. Leerink Swann set a $72.00 price objective on shares of Gilead Sciences and gave the company a “market perform” rating in a report on Wednesday, May 2nd. BidaskClub lowered shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a research note on Friday, May 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, May 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $88.14.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply